Developer docs
API playgroundTry for free, no card

Search company profiles

F2G

Full company profile

uuid0000lqa

Namestring
F2G
Legal namestring
F2G Ltd
Websiteurl
http://www.f2g.com
Company typeenum
Private
Founded yearint
1998
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersManchester, United Kingdom
HQ citystring
Manchester
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antifungal therapeutics, rare fungal infections, novel drug discovery, biopharmaceutical development, invasive aspergillosis treatment
Industry1 code
1Infectious Disease & Antimicrobials Pharmaceuticals
CodeHLAIAAAGPrimaryYes
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Antifungal Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product sales (pre-revenue)
TypeOne Time License
Description

F2G is a pre-revenue biopharma company. The company is developing olorofim for the treatment of invasive aspergillosis and coccidioidomycosis, with late-stage clinical development underway. Revenue will be generated through product sales following regulatory approval.

f2g.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

F2G discovers and develops novel antifungal therapeutics, with its lead candidate olorofim being the first member of the orotomide class — small molecules that selectively inhibit fungal dihydroorotate dehydrogenase (DHODH) to treat invasive aspergillosis, coccidioidomycosis, and rare resistant mold infections. The company is developing olorofim in oral (Phase 3), IV, inhaled, and pediatric formulations targeting immunocompromised patients who have failed standard azole therapy. F2G is a pre-revenue late-stage biotech preparing regulatory submissions following positive Phase 3 OASIS trial results in June 2026.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 3 OASIS trial: All-cause mortality at Day 42 was 23.8% for olorofim vs 24.3% for AmBisome (non-inferiority demonstrated).
+2 more records
Product overview1 text field

F2G is a biopharmaceutical company developing a focused portfolio of novel antifungal therapeutics centered on its lead candidate olorofim. The company has pioneered the orotomides class of antifungal agents that work through a novel dihydroorotate dehydrogenase (DHODH) inhibition mechanism. The core offering consists of olorofim available in multiple formulations: oral tablets for adult patients (Phase 3), IV formulation, inhaled formulation, and pediatric oral formulation. F2G operates a partnership with Shionogi for commercialization rights in certain regions and is preparing for regulatory submissions following positive Phase 3 OASIS trial results.

Product and service5 records
1Olorofim (oral antifungal)
CategoryAntifungal pharmaceutical — oral formulation
2Olorofim IV Formulation
CategoryAntifungal pharmaceutical — IV formulation
3Olorofim Inhaled Formulation
CategoryAntifungal pharmaceutical — inhaled formulation
4Olorofim Pediatric Oral Formulation
CategoryAntifungal pharmaceutical — pediatric formulation
5Early Access Program (compassionate use) for olorofim
CategoryCompassionate use / early access program
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Shionogi & Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Shionogi entered a collaboration with F2G for the development and commercialization of olorofim, a novel antifungal agent, with potential deal value of up to $480 million including upfront and milestone payments. F2G and Shionogi jointly conducted the global Phase 3 OASIS trial. Following positive Phase 3 results in June 2026, Shionogi plans regulatory submissions in Europe and Asia, while F2G plans submission in the US.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Scynexis
TypeDirect peer
Description

Scynexis developed ibrexafungerp (Brexafemme), a novel antifungal approved for vulvovaginal candidiasis and in development for invasive fungal infections. It is a direct peer as another late-stage antifungal biotech developing first-in-class mechanisms for serious and resistant fungal infections.

2Cidara Therapeutics
TypeDirect peer
Description

Cidara developed rezafungin (Rezzayo), an echinocandin antifungal approved for invasive candidiasis. It is a direct peer as an antifungal-focused biotech developing novel agents for invasive fungal infections in hospital settings.

3Amplyx Pharmaceuticals (Pfizer)
TypeDirect peer
Description

Amplyx developed fosmanogepix, a novel antifungal for invasive fungal infections including aspergillosis, and was acquired by Pfizer in 2021. It is a direct peer as a developer of a first-in-class antifungal targeting DHODH-adjacent pathways for resistant mold infections.

4Basilea Pharmaceutica
TypeDirect peer
Description

Basilea developed isavuconazole (Cresemba) for invasive aspergillosis and mucormycosis and has a pipeline of antifungal agents. It is a direct peer as an antifungal-focused company competing in invasive mold infection treatment.

5Melinta Therapeutics
TypeDirect peer
Description

Melinta is a specialty anti-infectives company with antifungal and antibiotic offerings targeting serious infections. It is a direct peer as a focused anti-infectives company developing and commercializing therapies for hospital-treated infections.

6Pfizer
TypeBroad incumbent
Description

Pfizer markets AmBisome (the comparator in F2G's Phase 3 trial) and voriconazole, and acquired Amplyx's fosmanogepix program. As the incumbent in invasive aspergillosis therapy, Pfizer is the broad competitor olorofim will displace or compete against in hospital formularies.

7Merck & Co.
TypeBroad incumbent
Description

Merck has historical antifungal franchises and infectious disease expertise. It is a broad incumbent in the antifungal and broader anti-infectives space against which olorofim will compete for hospital share and prescriber attention.

8Astellas Pharma
TypeBroad incumbent
Description

Astellas markets Cresemba (isavuconazole) outside the US for invasive aspergillosis through partnership and has a broader antifungal presence via historical venture investments. It is a broad incumbent overlapping with olorofim's target indications.

9Shionogi & Co.
TypeOthers
Description

Shionogi is F2G's $480M commercialization partner for olorofim in Europe and Asia. As a partner with shared economics and strategic interest in antifungal success, Shionogi is the most directly economically-linked company and a related player rather than a direct competitor.

10T2 Biosystems
TypeOthers
Description

T2 Biosystems develops diagnostic panels for invasive fungal infections and bloodstream infections. It is an adjacent player enabling earlier detection of the same patient population F2G targets with olorofim, making it thematically related but not a direct competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles23 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

F2G

Antifungal Pharmaceuticalsf2g.com

F2G firmographics

Firmographics
Name
F2G
Legal name
F2G Ltd
Website
http://www.f2g.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

F2G industry classification

Industry
Product category
Antifungal Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

  • Antifungal therapeutics
  • Rare fungal infections
  • Novel drug discovery
  • Biopharmaceutical development
  • Invasive aspergillosis treatment

Where F2G is headquartered

Location

Headquarters

HQ city
Manchester
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

F2G business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical product sales (pre-revenue): F2G is a pre-revenue biopharma company. The company is developing olorofim for the treatment of invasive aspergillosis and coccidioidomycosis, with late-stage clinical development underway. Revenue will be generated through product sales following regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

F2G product offering

Product offering

Core offering

F2G discovers and develops novel antifungal therapeutics, with its lead candidate olorofim being the first member of the orotomide class — small molecules that selectively inhibit fungal dihydroorotate dehydrogenase (DHODH) to treat invasive aspergillosis, coccidioidomycosis, and rare resistant mold infections. The company is developing olorofim in oral (Phase 3), IV, inhaled, and pediatric formulations targeting immunocompromised patients who have failed standard azole therapy. F2G is a pre-revenue late-stage biotech preparing regulatory submissions following positive Phase 3 OASIS trial results in June 2026.

Product overview

F2G is a biopharmaceutical company developing a focused portfolio of novel antifungal therapeutics centered on its lead candidate olorofim. The company has pioneered the orotomides class of antifungal agents that work through a novel dihydroorotate dehydrogenase (DHODH) inhibition mechanism. The core offering consists of olorofim available in multiple formulations: oral tablets for adult patients (Phase 3), IV formulation, inhaled formulation, and pediatric oral formulation. F2G operates a partnership with Shionogi for commercialization rights in certain regions and is preparing for regulatory submissions following positive Phase 3 OASIS trial results.

Differentiator

Problem solved

Functional benefit

Products and services

  • Olorofim (oral antifungal)
  • Olorofim IV Formulation
  • Olorofim Inhaled Formulation
  • Olorofim Pediatric Oral Formulation
  • Early Access Program (compassionate use) for olorofim

Quantifiable outcome

  • Phase 3 OASIS trial: All-cause mortality at Day 42 was 23.8% for olorofim vs 24.3% for AmBisome (non-inferiority demonstrated).
  • +2 more outcomes

Companies that use F2G

Customer profile

Segments1 record

Ideal customer profiles1 record

F2G technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

F2G partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Shionogi & Co., Ltd.coreStrategic or Co-development PartnerShionogi entered a collaboration with F2G for the development and commercialization of olorofim, a novel antifungal agent, with potential deal value of up to $480 million including upfront and milestone payments. F2G and Shionogi jointly conducted the global Phase 3 OASIS trial. Following positive Phase 3 results in June 2026, Shionogi plans regulatory submissions in Europe and Asia, while F2G plans submission in the US.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

F2G competitors and assessment

Company assessment

Direct peers

  • Scynexis: Scynexis developed ibrexafungerp (Brexafemme), a novel antifungal approved for vulvovaginal candidiasis and in development for invasive fungal infections. It is a direct peer as another late-stage antifungal biotech developing first-in-class mechanisms for serious and resistant fungal infections.
  • Cidara Therapeutics: Cidara developed rezafungin (Rezzayo), an echinocandin antifungal approved for invasive candidiasis. It is a direct peer as an antifungal-focused biotech developing novel agents for invasive fungal infections in hospital settings.
  • Amplyx Pharmaceuticals (Pfizer): Amplyx developed fosmanogepix, a novel antifungal for invasive fungal infections including aspergillosis, and was acquired by Pfizer in 2021. It is a direct peer as a developer of a first-in-class antifungal targeting DHODH-adjacent pathways for resistant mold infections.
  • Basilea Pharmaceutica: Basilea developed isavuconazole (Cresemba) for invasive aspergillosis and mucormycosis and has a pipeline of antifungal agents. It is a direct peer as an antifungal-focused company competing in invasive mold infection treatment.
  • Melinta Therapeutics: Melinta is a specialty anti-infectives company with antifungal and antibiotic offerings targeting serious infections. It is a direct peer as a focused anti-infectives company developing and commercializing therapies for hospital-treated infections.

Broad incumbents

  • Pfizer: Pfizer markets AmBisome (the comparator in F2G's Phase 3 trial) and voriconazole, and acquired Amplyx's fosmanogepix program. As the incumbent in invasive aspergillosis therapy, Pfizer is the broad competitor olorofim will displace or compete against in hospital formularies.
  • Merck & Co. Merck has historical antifungal franchises and infectious disease expertise. It is a broad incumbent in the antifungal and broader anti-infectives space against which olorofim will compete for hospital share and prescriber attention.
  • Astellas Pharma: Astellas markets Cresemba (isavuconazole) outside the US for invasive aspergillosis through partnership and has a broader antifungal presence via historical venture investments. It is a broad incumbent overlapping with olorofim's target indications.

Others

  • Shionogi & Co. Shionogi is F2G's $480M commercialization partner for olorofim in Europe and Asia. As a partner with shared economics and strategic interest in antifungal success, Shionogi is the most directly economically-linked company and a related player rather than a direct competitor.
  • T2 Biosystems: T2 Biosystems develops diagnostic panels for invasive fungal infections and bloodstream infections. It is an adjacent player enabling earlier detection of the same patient population F2G targets with olorofim, making it thematically related but not a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

F2G social profiles

Digital presence

F2G compliance and trust

Trust signal

Compliance2 records

F2G financial estimates

Financial estimate

Revenue estimate

Valuation estimate

F2G leadership team

Management profile

Number of profiles

Profiles23 records

F2G subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

F2G funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

F2G M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about F2G

What does F2G do?

F2G discovers and develops novel antifungal therapeutics, with its lead candidate olorofim being the first member of the orotomide class — small molecules that selectively inhibit fungal dihydroorotate dehydrogenase (DHODH) to treat invasive aspergillosis, coccidioidomycosis, and rare resistant mold infections. The company is developing olorofim in oral (Phase 3), IV, inhaled, and pediatric formulations targeting immunocompromised patients who have failed standard azole therapy. F2G is a pre-revenue late-stage biotech preparing regulatory submissions following positive Phase 3 OASIS trial results in June 2026.

Is F2G a public or private company?

F2G is a private company. It is classified as venture growth investor backed and is currently operating.

When was F2G founded?

F2G was founded in 1998. It employs 51 to 100 people.

Where is F2G based?

F2G is headquartered in Manchester, United Kingdom, in the Europe region.

How does F2G make money?

One revenue line is on record: pharmaceutical product sales (pre-revenue).

Who are F2G's main competitors?

Direct peers on record are Scynexis, Cidara Therapeutics, Amplyx Pharmaceuticals (Pfizer), Basilea Pharmaceutica and Melinta Therapeutics. Broad incumbents are Pfizer, Merck & Co. and Astellas Pharma. Others are Shionogi & Co. and T2 Biosystems.

Does F2G have an API?

No public API is recorded for F2G.

What industry is F2G in?

F2G's product category is Antifungal Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The University of ManchesterDeadly mould strains highly likely to acquire resistance to new drugsResearchers from the University of Manchester have identified strains of Aspergillus fumigatus that are not only resistant to current azole drugs but are also five times more likely to develop resistance to new antifungal treatments in development. This heightened resistance is driven by genetic changes in the fungus's DNA mismatch repair system, which accelerates its evolution and poses a significant public health threat. The findings underscore the urgent need for innovative strategies to combat antifungal resistance, particularly given the reliance on F2G Ltd's olorofim for treating these infections.IdseInvasive Aspergillosis Phase 3 Positive Olorofim ResultsF2G and Shionogi announced positive topline results from the phase 3 OASIS trial of olorofim for invasive aspergillosis, demonstrating noninferiority against liposomal amphotericin B with a lower rate of treatment-emergent adverse events. The study met its primary endpoint, showing comparable all-cause mortality between the drug and control therapy while highlighting a more favorable safety profile for olorofim. Full data are currently being submitted to the FDA and other international regulatory agencies for review.Clinical Trials ArenaShionogi and F2G report positive top line data from Phase III OASIS studyShionogi and F2G reported positive top-line data from the global OASIS Phase III study of olorofim in invasive aspergillosis, achieving non-inferiority with an all-cause mortality rate of 23.8% versus 24.3% for AmBisome plus standard of care. Drug-related adverse events were 35.8% for olorofim versus 63.9% for the comparator, with no new safety concerns. Full results will be presented at an upcoming medical congress.FierceBiotechF2G, Shionogi prep regulatory push after novel antifungal passes ph. 3 testF2G and Shionogi have released phase 3 OASIS trial data demonstrating that their novel oral antifungal olorofim is non-inferior to AmBisome for treating invasive aspergillosis, with comparable mortality rates (23.8% vs 24.3% at day 42) but significantly fewer adverse events (35.8% vs 63.9%). The drug represents the first new mechanism of action for this life-threatening fungal infection in over 20 years, working through dihydroorotate dehydrogenase inhibition to target azole-resistant strains. F2G and Shionogi plan regulatory submissions in the U.S. and in Europe/Asia, respectively, following these results.GlobeNewswireF2G and Shionogi Announce Positive Topline Results From Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients With Invasive AspergillosisF2G Ltd and Shionogi & Co., Ltd announced positive topline results from the global Phase 3 OASIS study evaluating oral antifungal drug olorofim versus AmBisome® followed by standard of care in patients with invasive aspergillosis refractory to or unsuitable for azole therapy. The study met its primary endpoint of non-inferiority with all-cause mortality at Day 42 of 23.8% for olorofim versus 24.3% for AmBisome® followed by SOC. If approved, olorofim would become the first novel mechanism agent for invasive aspergillosis in over 20 years, with a significantly lower rate of drug-related adverse events (35.8% vs 63.9%).European BiotechnologyF2G’s oral antifungal clears Phase III hurdleF2G and Shionogi reported positive topline results from the global Phase III OASIS trial of oral olorofim in invasive aspergillosis. The drug met non-inferiority, with Day 42 mortality of 23.8% versus 24.3% for AmBisome, and fewer drug-related adverse events. Detailed data are expected at a future meeting.GlobeNewswireF2G and Shionogi Announce Positive Topline Results From Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients With Invasive AspergillosisF2G and Shionogi announced positive topline results from the global Phase 3 OASIS study comparing oral olorofim to AmBisome followed by standard of care in invasive aspergillosis. The study met non-inferiority, with all-cause mortality at Day 42 of 23.8% for olorofim versus 24.3% for AmBisome, and drug-related TEAEs of 35.8% versus 63.9%. Results will be submitted to regulatory authorities in the U.S., Europe, and Asia.The Pharma LetterF2G and Shionogi set up regulatory push for olorofim after Phase III winBritish biotech F2G and Japanese pharma Shionogi reported positive top-line Phase III results for olorofim, their investigational oral antifungal for invasive aspergillosis, with the global OASIS study meeting its primary endpoint. The trial demonstrated olorofim was non-inferior to AmBisome (liposomal amphotericin B) in patients who cannot use or have not responded to standard azole therapy. The companies are now preparing for regulatory submission following this pivotal Phase III success.BusinessLineBright spots in tackling AMRs, but drug-resistance outpaces pharma industry efforts: ReportThe Access to Medicine Foundation's 2026 AMR Benchmark report finds that drug resistance is outpacing industry-wide efforts, while identifying seven innovative late-stage projects from GSK, Otsuka, Shionogi, BioVersys, F2G, Innoviva, and Venatorx targeting drug-resistant pathogens. Over one million people die annually from drug-resistant infections, with projections indicating direct deaths could rise to nearly two million and indirect deaths to over eight million by 2050. The performance of large research-based companies and generic medicine manufacturers has declined since 2021, though GSK, Aurobindo, and Shionogi were recognized as leading performers among the 25 companies evaluated.Endpoints NewsF2G CEO out­lines biotech's FDA re­sub­mis­sion plans, fund­ing and ex­pan­sionF2G, a biotech company, plans to resubmit its antifungal drug candidate to the FDA after collecting Phase 3 data expected in June, according to CEO Francesco Maria Lavino speaking to Endpoints News. The CEO outlined plans for funding and expansion alongside the regulatory resubmission strategy. The FDA resubmission represents a key milestone in the drug's path toward potential approval.